RxDoctor Payments Data

William Ko, MD

Pain Medicine · Fullerton, CANPI 1629011762

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 51 payments — averaging $31.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$970
  • Boston Scientific$85
  • Johnson & Johnson$60
  • Pfizer$58
  • Nevro Corp.$53
  • Daiichi Sankyo Inc.$50
  • plus $337 from 12 others

What the payments were for

  • Food & beverage$1,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)21$970
Boston Scientific3$85
Johnson & Johnson2$60
Pfizer4$58
Nevro Corp.2$53
Daiichi Sankyo Inc.3$50
Biotronik NRO, Inc.1$42
AbbVie2$42
Scilex Pharmaceuticals Inc.2$36
Averitas Pharma Inc.1$36
Vertex1$34
Curonix LLC2$33
Collegium Pharmaceutical, Inc.2$29
IBSA Pharma Inc.1$19
West Therapeutics Development, LLC1$19
Amgen1$17
Sentynl Therapeutics, Inc.1$16
Assertio Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,613 in reported general payments places this provider in the 45th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$170,382
Medicare patients
262
Services billed
3,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen459$14,135
NucyntaTapentadol Hcl11$10,617
Fentanyl69$9,721
MovantikNaloxegol Oxalate13$5,217
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen192$4,971
Morphine Sulfate ErMorphine Sulfate142$3,399
Gabapentin301$3,253
Lidocaine26$3,119
Oxycodone Hcl105$1,762
Methadone Hcl79$1,608
Acetaminophen-CodeineAcetaminophen With Codeine55$1,458
Baclofen119$1,219
Morphine Sulfate43$1,202
Naloxone Hcl20$1,026
Pregabalin52$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$29$10,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 840 pain medicine providers in California.

Other pain medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →